Enzon Pharmaceuticals, Inc.
http://enzon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Enzon Pharmaceuticals, Inc.
Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Biocon Expects US b(Humira) Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Unilabs Signs Multi-Year Deal With C2N To Expand Alzheimer’s Test In Europe And Beyond
Unilabs and C2N Diagnostics signed a multi-year agreement that will expand access to C2N’s Alzheimer’s tests in Europe and other countries.
Lupin And Zentiva Snatch First Generic Raltegravir Approval In UK
The UK’s MHRA has approved the first generic raltegravir to treat HIV in adults and certain pediatric patients and deemed the drug interchangeable with the originator Isentress.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice